Randomized phase II study of pembrolizumab after stereotactic body radiotherapy (SBRT) versus pembrolizumab alone in patients with advanced non-small cell lung cancer: The PEMBRO-RT study.-Reference-Cited by-同舟云学术

Randomized phase II study of pembrolizumab after stereotactic body radiotherapy (SBRT) versus pembrolizumab alone in patients with advanced non-small cell lung cancer: The PEMBRO-RT study.

Published:2018-05-20 Issue:15_suppl Volume:36 Page:9023-9023
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Theelen Willemijn¹,H.Peulen@Nki.Nl No Firstname²,Lalezari Ferry³,de Vries Jeltje⁴,De Langen Joop⁵,Aerts Joachim⁶,Monkhorst Kim⁷,Baas Paul⁸

Affiliation:

1. Netherlands Cancer Institute, Amsterdam, Netherlands;

2. Catharina Hospital, Eindhoven, Netherlands;

3. NKI, Amsterdam, Netherlands;

4. NKI, Amsterdam`, Netherlands;

5. VU University Medical Center, Amsterdan, Netherlands;

6. Department of Pulmonology, Erasmus University Medical Center, Rotterdam, Netherlands;

7. Netherlands Cancer Institute, Department of Pathology, Amsterdam, Netherlands;

8. The Netherlands Cancer Institute (NKI), Amsterdam, Netherlands;

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2018.36.15_suppl.9023

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radiotherapy in the management of synchronous metastatic lung cancer;Cancer/Radiothérapie;2024-02

2. Palliative radiotherapy in oligometastases;Palliative Radiation Oncology;2024

3. A prospective study of immune responses in patients with lung metastases treated with stereotactic body radiotherapy with or without concurrent systemic treatment;2023-11-14

4. Systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer;npj Precision Oncology;2023-03-02

5. Toxicity When Combining Immunotherapy and Radiotherapy;Handbook of Cancer and Immunology;2023